The 20 Best Wilms Tumor Doctors near Flushing, NY

Guido Dalbagni is a Urologist in New York, New York. Dr. Dalbagni is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.

William Huang is a Urologist in New York, New York. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Nephrectomy, and Cystectomy.

Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Joph Steckel is a Urologist in Lake Success, New York. Dr. Steckel is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Jane Cho is an Oncologist and a Urologist in Rego Park, New York. Dr. Cho is rated as an Experienced provider by MediFind in the treatment of Wilms Tumor. Her top areas of expertise are Obstructive Uropathy, Bladder Cancer, Urinary Tract Infection (UTI), Cystectomy, and Ureteroscopy.

Christopher Hartman is a Urologist in Rego Park, New York. Dr. Hartman is rated as an Experienced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Obstructive Uropathy, Kidney Stones, Enlarged Prostate (BPH), Lithotripsy, and Ureteroscopy.

Ketan Badani is a Urologist in Long Island City, New York. Dr. Badani is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Reza Mehrazin is a Urologist in Long Island City, New York. Dr. Mehrazin is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Cystectomy.

Kai Tsao, MD, MS, is the system chief of solid tumor oncology, medical director of the R.J. Zuckerberg Cancer Center, and medical director of the medical oncology prostate cancer program at the Northwell Cancer Institute. He specializes in cancers of the genitourinary organs and has more than a decade of clinical experience. His research focuses on the development of biomarkers and novel therapies for patients with genitourinary cancers.Dr. Tsao was inspired to become an oncologist after witnessing many close family and friends suffering from cancer. He completed medical school training at SUNY Downstate, an internal medicine residency at Long Island Jewish Medical Center, and a fellowship in hematology and medical oncology at Mount Sinai Hospital. He earned a master's degree in healthcare delivery leadership at Icahn School of Medicine at Mount Sinai and completed Lean Six Sigma training at Johns Hopkins.Prior to joining Northwell, Dr. Tsao served as medical director of the Ruttenberg Treatment Center, medical director of the medical oncology prostate cancer program, and physician leader for internal oncology collaborations at the Mount Sinai Hospital, Tisch Cancer Institute. In these roles, Dr. Tsao and his team built a cancer center that is patient centered, quality driven, scientifically innovative, and provided multi-disciplinary care to patients with cancer.For me, patient care much more than the cancer diagnosis and treatment. It is essential to address the many needs of our cancer patients: emotional well-being, social support, nutrition, physical activity, financial challenges and more. We aim to provide the best support for our patients, one at a time.Dr. Tsao is an accomplished physician-scientist who has authored more than 80 peer-reviewed publications in the field of genitourinary oncology. He serves as associate editor of Genitourinary Oncology, Frontiers in Oncology. His leadership in carrying out complex clinical trials in targeted therapies and immunotherapies positions his patients at the forefront of cutting-edge cancer research and patient-centered care.What I most enjoy every day is seeing patients under our care, despite the devastation of their cancer diagnosis, beating their cancer and living a life that was not considered a possibility years ago. Our mission at Northwell Cancer Institute is to make this a reality for every single patient. Dr. Tsao is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Orchiectomy, and Nephrectomy.

James Wysock is a Urologist in New York, New York. Dr. Wysock is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Urachal Cyst, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

Vladimir Gotlieb is a Hematologist and an Oncologist in Forest Hills, New York. Dr. Gotlieb is rated as an Experienced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Leukocytosis, Smoldering Multiple Myeloma, Multiple Myeloma, Paget Disease of the Breast, and Bone Marrow Aspiration.

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Nephrectomy.

Julie Krystal is a Pediatrics specialist and an Oncologist in New Hyde Park, New York. Dr. Krystal is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. Her top areas of expertise are Neuroblastoma, Medulloblastoma, Acute Lymphoblastic Leukemia (ALL), Rhabdomyosarcoma, and Bone Marrow Aspiration.

Lee Richstone, MD is the Chairman of Urology and Director of Urology Services for the Western Region. He is also Director of Laparoscopic and Robotic Surgery at Lenox Hill Hospital and System Vice Chairman for Education for Northwell Health Urology. Dr. Richstone is Professor of Urology at The Hofstra-Northwell School of Medicine. Dr. Richstone completed medical school at the Cornell University Medical College in New York City. There he won early acceptance into Alpha Omega Alpha (AOA), the prestigious national medical honor society. He pursued his urologic training and chief residency at New York Presbyterian (Weill-Cornell) and Memorial Sloan Kettering hospitals. Dr. Richstone completed his fellowship training in urologic laparoscopic and robotic surgery and joined the North Shore Long Island Jewish Health System in 2007 as Director of Laparoscopic and Robotic Surgery. He then served as Chief of Urology for the North Shore University Hospital, then Chief of Urology at the Long Island Jewish Medical Center, before assuming the role of Chairman of Urology at Lenox Hill Hospital in Manhattan. Dr. Richstone is an internationally recognized urologic surgeon who has helped pioneer laparoscopic and robotic surgery for cancer of the prostate, kidney and bladder, as well as for various forms of urinary obstructions. He has over 90 peer-reviewed publications in leading national and international journals including The Journal of Urology, Urology, The British Journal of Urology, The Journal of Endourology, Cancer, and Cell.Dr. Richstone is a robotic surgery specialist having performed well over 1000 operations. This includes surgeries for prostate, kidney and bladder cancer and complex neobladder reconstructions completely robotically. His focus is on preserving urinary continence and sexual function. Dr. Richstone has also pioneered Laparoendoscopic Single Site Surgery (LESS), where entire laparoscopic operations are performed only through the belly button. Dr. Richstone is one of only a few surgeons in the United States to have performed single site partial nephrectomy and prostatectomy.Dr. Richstone is a member of the Society of Urologic Oncology (SUO), the America Urological Association (AUA), and the Endourological Society (EUS). Dr. Richstone is the recipient of numerous honors and awards, including acceptance into Alpha Omega Alpha (AOA), the E. Darracott Vaughan Prize for Excellence in Urology (2000), The Ferdinand C. Valentine Urology Essay Prize (First Place, 2005), The American Urological Association-Ambrose Reed Socioeconomic Essay Contest (First Place, 2005), and the Weill-Cornell Distinguished House Officer Award (2005). Dr. Richstone was awarded the Stryker and Nagamatsu Fellowship (2007), and won first prize at the Endourology Society Fellowship Paper Award the same year. Dr. Richstone won first prize at the AUA Research Foundation for Outstanding Research awarded at the 2010 AUA National Meeting in San Francisco. Dr. Richstone is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

"Xinhua Zhu, MD, PhD, is a medical oncologist and hematologist at Monter Cancer Center, where he specializes in treating genitourinary cancer, including cancer of the prostate, kidney, bladder and testicles. He focuses on compassionate, evidence-based care, rooted in his research background.""My research helps me think outside the box when creating treatment plans,"" says Dr. Zhu, ""and enables me to explain to patients the mechanisms behind the treatments I'm using."" His research interests include finding new treatment targets for generating hormone resistance in prostate cancer and metastatic castration-resistant prostate cancer, exploring biomarkers in bladder cancer to guide decisions about chemotherapy, exploring the mechanisms for kidney cancer metastasis, and investigating the effectiveness of immunotherapy for genitourinary cancers.Dr. Zhu earned his medical degree at Suzhou Medical College and practiced internal medicine in China. He obtained his PhD in cancer study at Shanghai Jiao Tong University School of Medicine, then moved to the United States for postdoctoral research training at Memorial Sloan Kettering Cancer Center, an internal medicine residency at Mount Sinai School of Medicine. He attended NYU School of Medicine for fellowship training in hematology and medical oncology.In 2013, he joined Northwell Health, where he regularly meets with a multidisciplinary group of pathologists, radiologists, radiation oncologists, surgical oncologists, geneticists and the Molecular Tumor Board to create treatment plans.As an associate professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, he twice received the Medical Oncology/Hematology Fellowship Program Teacher of the Year Award. Dr. Zhu is also a phase 1 cancer research program director at Monter Cancer Center. He is assistant investigator at the Feinstein Institutes for Medical Research, and a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Principal Investigator for the Northwell Health NCI Community Oncology Research Program (NCORP)For Dr. Zhu, being able to pursue both scientific investigation and patient care is the best part of his work. ""I can take research from the bench to the bedside, providing people with the best possible treatments,"" he says.". Dr. Zhu is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Ariel Schulman is a Urologist in Brooklyn, New York. Dr. Schulman is rated as an Experienced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Bladder Cancer, Prostatectomy, and Nephrectomy.

David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer. Dr. Loeb is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.